Get started
TamJai: Another Haidilao + Nongfu Spring in HK stock sector- Why it is like Haidilao: Business model advantages: Cost: They don't need a massive change to their receipts. Expansion: Simple value chain make its expansion becomes very easy. - Unique favor from Hong Kong: Most locals craves to eat TamJai products after they're leaving the city for a while. This create an opportunity for them to expand their business after covid period. - Why it is like Nongfu spring: Strong players in play: Highly centralized by a Japanese firm and they are also keep holding 70%+ of their position tight. A lot of opportunities for this brand to expand globlly. Meanwhile the PE ratio is not that high, comparing with their parent company toridoll (3397.T).
HKEX:2217Long
by BillionaireLau
700 (HKEX) - Another idea that slap youHello, if you are the true investor, someone who has big amount of cash to invest in stock, absolutely u will reasearch for big market cap stock which can give you more stability and also gain. At the long term, we can see that tencent is bullish, so it give more opportunity to keep you safe even you are enter in wrong time. so what is the idea now : 1. We need to see, what is the indication that show if the bearish already stop and the trend will changing 2. if you are long term investor, this time is best to do research for buying preparation If you have more data, not only about fundamental but also list of stock holder, broker summary, u will make sure it is time to buy or still waiting. But the chart really nice If you have any question, feel free to send us message. ALL is FREE NB : Not Financial advise
HKEX:700
by MultiAssetX
Evergrande holds bearish Elliot waves In our last posting on Evergrande in October we pointed out the Elliot wave structure in price. This made a high around the price point we posted and has went into a solid downtrend ever since. The fear/attention/concern over the Evergrade situation flared up quickly. It seemed like overnight everyone became an expert in the China property market (Excluding those who actually posted incredible analysis on Evergrande/China debt bubble long before it became popular). This faded away almost as fast as it appeared - but the chart has not stopped painting the warnings.
HKEX:6666Short
by holeyprofit
JD.com's Healthcare Unit Prepare for Next Battle Affected heavily by recent technological advancements, the sector may soon attract Chinese regulators' attention. Background 2021 turned out to become a positive year for China's healthcare industry, where the gigantic demand stems from the aging population, growing individual wealth, and – more importantly – the COVID-19 crisis' aftermath. The market has grown consistently; in 2020, the growth rate slumped to 7.2% due to the massive lockdowns, although it is expected to rise back to 17.6% in 2021 with a total market size of CNY 8.7 trillion. Despite this, the market remains relatively undeveloped – since 2016, the Chinese authorities have been working on creating a CNY 16 trillion healthcare ecosystem by 2030. Online healthcare is in the limelight The pandemic challenged people's sense of well-being and facilitated their desire and determination to become more active and engaged in managing their health, which also boosted the need for remote medical consultations and online medicine sales. According to Deloitte, the portion of consumers who have used virtual visits rose from 15% to 19% from 2019 to early 2020, then jumped to 28% in April 2020. In fact, consumers plan to continue using the – 80% of the Deloitte survey respondents are likely to keep using other online services even post COVID-19. Jessica Tan, co-CEO of Ping An Group, once said that around 20% to 25% of healthcare services in China could be moved to the online space. This will present new opportunities to the most competitive businesses in this field. Among these, JD Health (6618:HK) and Alibaba Health (0241:HK) are two tech giant-backed companies that have ridden this surging wave quite well. The latecomer, JD Health, is moving really fast – only four months' independent operation since May 2019 before it filed a public offering. In August 2020, JD Health ranked 35th on Hurun Global Unicorn Index 2020 with a valuation at CNY 50 billion, which crowned it as the world's youngest unicorn. Different from traditional platforms, JD Health has established various online and offline integrated businesses, including JD Pharmacy, JD Health Internet Hospital and Pharmacy Alliance. How does JD.com compare in healthcare endeavors? Financial performance In September 2021, JD Health released its interim financial report with relatively strong results. Its total revenue increased by over half (55.4%), from CNY 8.8 billion in H1 2020 to CNY 13.6 billion in H1 2021, which was primarily due to the increase in revenue from sales of pharmaceutical and healthcare products within the reporting period. In fact, this continuous upward trend also shows in its gross profit for the past four fiscal years, although the loss enlarged even further in 2020 when compared with the previous years. Another catalyst for the growth could be the increase in JD Health's number of Annual Active User (AAU) accounts. As of June 30, 2021, the AAUs in the past 12 months reached 109 million, representing a net addition of over 18.8 million as compared with that of 2020. The growing number also shows that the stickiness of users has been well improved as well as its brand awareness. In other words, JD Health's constant investment in marketing activities – its selling and marketing expenses almost doubled for two consecutive fiscal years – finally began to work. JD's supply chain infrastructure casts its core barrier Although JD Health is relatively inferior to its competitor in terms of annual active users – 109 million as of June 30, 2021 – JD Health's revenue is all the way higher than that of its closest competitor, Alibaba Health, more specifically, the revenue as nearly two times higher. One booster is its complete business structure. Integrating B2B/B2C/O2O businesses, JD Health can have more wings – for example, along with the retail pharmacy, JD Health also offers its own family doctor services, online hospital services as well as smart healthcare solutions. Through the integration of pharmaceutical retail businesses and online healthcare services, the medical products users also become target customers for other consumption healthcare units, and vice versa; a closed cycle hence is developed and can also be seen in its ever-growing operating income at a CAGR of 11%. JD Logistics is another catalyst supporting the healthcare unit's strong performance, being one of the leading supply chain players in the field of medicine now. Through JD Logistics, JD Health is able to connect with upstream, midstream and downstream enterprises: from industrial enterprises and healthcare institutions to offline pharmacies and dental clinics. This absolute advantage over comparable companies enables JD Health to further cut its fulfillment costs to around 10% of total revenue, which is related to warehousing, logistics and customer service expenditures incurred by the self-operated pharmaceutical business. Future in the mist The future won't be easy for both Alibaba Health and JD Health, as the competition is intensifying. Except for the 'peer pressure,' some inherent problems exist in the essence of most healthcare services – those are mainly related to professionalism, trust and quality. It is partly because of the particularity of healthcare services and pharmaceutical drugs along with the recent market chaos, the government has tightened supervision increasingly, more than ever before. Rory Green, a China economist at TS Lombard, said that the healthcare sector is the only one not hit by regulatory scrutiny yet but is particularly vulnerable, which may possibly make it the next target. For the full article with the charts, please visit the original link.
HKEX:6618
by EqualOcean
Alibaba Healthcare Units Prepares for Next Battle in HealthcareAffected heavily by recent technological advancements, the sector may soon attract Chinese regulators' attention. Background 2021 turned out to become a positive year for China's healthcare industry, where the gigantic demand stems from the aging population, growing individual wealth, and – more importantly – the COVID-19 crisis' aftermath. The market has grown consistently; in 2020, the growth rate slumped to 7.2% due to the massive lockdowns, although it is expected to rise back to 17.6% in 2021 with a total market size of CNY 8.7 trillion. Despite this, the market remains relatively undeveloped – since 2016, the Chinese authorities have been working on creating a CNY 16 trillion healthcare ecosystem by 2030. Online healthcare is in the limelight The pandemic challenged people's sense of well-being and facilitated their desire and determination to become more active and engaged in managing their health, which also boosted the need for remote medical consultations and online medicine sales. According to Deloitte, the portion of consumers who have used virtual visits rose from 15% to 19% from 2019 to early 2020, then jumped to 28% in April 2020. In fact, consumers plan to continue using the – 80% of the Deloitte survey respondents are likely to keep using other online services even post COVID-19. Jessica Tan, co-CEO of Ping An Group, once said that around 20% to 25% of healthcare services in China could be moved to the online space. This will present new opportunities to the most competitive businesses in this field. Among these, JD Health (6618:HK) and Alibaba Health (0241:HK) are two tech giant-backed companies that have ridden this surging wave quite well. Alibaba (BABA:NASDAQ) is deemed to be the first explorer among Chinese tech giants, having joined the game as early as 1998 by founding Alibaba Health (0241:HK). In fact, it is the first Chinese Internet-healthcare company to go public on the Hong Kong Stock Exchange. Alibaba Health is primarily engaged in the pharmaceutical direct sales business, the pharmaceutical e-commerce platform business, medical and healthcare services platforms and digital infrastructure business and related services, though it wants to take off the 'e-pharmacy' tag for long. How does Alibaba compare in the healthcare endeavors? Financial Performance Alibaba Health finally became fully profitable in its fiscal 2021, when the revenue reached CNY 15.52 billion Among four major businesses, medicine remains the main contributor to its revenue, amounting to CNY 13.21 billion, or about 85% of the total revenue. The rest is contributed by pharmaceutical e-commerce platform business, the medical health service business and digital infrastructure business, with revenues of CNY 1.96 billion, CNY 284 million and CNY 53 million respectively. Benefiting from the improving cost control ability and the emerging economies of scale, the overall expenses of Alibaba Health are far less than that of JD Health for every comparable fiscal year. BABA's backing is the ace card of Alibaba Health As the healthcare business arm of Alibaba Group, the natural traffic comes with related brand benefits; Alibaba Health's core pharmaceutical direct sales and e-commerce platform businesses are thus boosted to a great extent. Three specific edges are worth mentioning. First, brand power drives growth. In 2021, Alibaba has grown its brand value by 32% year-on-year to USD 201.86 billion, with a 2nd ranking domestically and 7th ranking globally. As one of the most valuable brands, consumers are more likely to pay a value premium for the products with this recognizable name, or for the creditability it owns. This is indeed what is going on with Alibaba Health. For the 12 months ended March 31, 2021, the revenue from drugs generated from the pharmaceutical direct sales business under the brand of 'Alibaba Health' increased by 86.1% year-on-year, accounting for 64.8% of the revenue of the business. And the number of annual active users of the direct online stores in the reporting period reached a record high of 81 million. Second, synergistic benefits of Alibaba's ecosystem. The synergy effect is most difficult or even impossible to be imitated by competitors. When looking back at Alibaba's business scope, we could see it has already laid out a lot – Alipay's insurance services and 'Future Hospital' plan, O2O medicine delivery service on takeaway platform and hospital-specialized modules on DingTalk – most major businesses owned by Alibaba have medical-related s. With continuous investment in these business-to-consumer marketplace made by the Group, Alibaba Health is able to enhance health awareness and acquire new customers at relatively low acquisition costs, which lays a strong foundation for future growth. As of March 31, 2021, the number of annual active users had exceeded 280 million on Tmall's Pharmaceutical Platform while Alipay's healthcare channel as a whole reached over 520 million annual active users for the fiscal year. Third, empowerment of big data. As a wholly-owned subsidiary of Alibaba with deep roots in the Internet, Alibaba Health's capabilities and resources are naturally geared towards leveraging the prowess of the Internet, big data and Cloud computing. To further boost its digital infrastructure business, for example, tracking platform 'Ma Shang Fang Xin' and digital health business, Alibaba Health has been working closely with Alibaba Cloud to lead the healthcare area. In addition, it also focuses on digital infrastructure. Based on the Group's internal AI, big data, payment and IT capabilities, Alibaba Health is working on exploring the construction of intelligent medical systems, such as AI-assisted diagnostic decision-making, remote imaging platforms and blockchain data security solutions in major hospitals and regions. Future in the mist The future won't be easy for both Alibaba Health and JD Health, as the competition is intensifying. Except for the 'peer pressure,' some inherent problems exist in the essence of most healthcare services – those are mainly related to professionalism, trust and quality. It is partly because of the particularity of healthcare services and pharmaceutical drugs along with the recent market chaos, the government has tightened supervision increasingly, more than ever before. Rory Green, a China economist at TS Lombard, said that the healthcare sector is the only one not hit by regulatory scrutiny yet but is particularly vulnerable, which may possibly make it the next target. For the full article with the charts, please visit the original link.
HKEX:241
by EqualOcean
Kuaishou : Short VDO leads to Social CommerceThough there is no TikTok stock to buy. But we have this company as representative of Short Video Social Network. Spending time per day for this category is most engaging / addictive. How knows that GMV on Kuaishou Platform is 3-4 times larger than Shopee. With Valuation around 50-60B range, comparing to MAU around 1B. Such a bargain at this point if company prove they can manage on profitability in next couple years. Recently growth has been driven from advertising and commerce side. and they grow up with fast pace than old business ( streaming virtual gift ) Assume CAGR 30-40% for a big while Also majority of users are living in tier 2-3-4-5 cities That is our focus. Due Government Policy and Demographics , we expect to see rising of middle class in rural area faster than urban Long Kuaishou Dec 2021
HKEX:1024Long
by gmhfund
Kuaishou : Short VDO leads to Social CommerceThough there is no TikTok stock to buy. But we have this company as representative of Short Video Social Network. Spending time per day for this category is most engaging / addictive. How knows that GMV on Kuaishou Platform is 3-4 times larger than Shopee. With Valuation around 50-60B range, comparing to MAU around 1B. Such a bargain at this point if company prove they can manage on profitability in next couple years. Recently growth has been driven from advertising and commerce side. and they grow up with fast pace than old business ( streaming virtual gift ) Assume CAGR 30-40% for a big while Also majority of users are living in tier 2-3-4-5 cities That is our focus. Due Government Policy and Demographics , we expect to see rising of middle class in rural area faster than urban Long Kuaishou Dec 2021
HKEX:1024Long
by gmhfund
HKG:3690 (Meituan) End of China Internet ?Meituan has been our 2nd largest position since 2020. Once we cashed out this stock out during late 2020 at 280~290HKD and then jump into US tech stock 100% at the end of 2020. We had an opportunity to buy this company again at lower price on Tech Crackdown & Common Prosperity policy. At first effect from bad news , stock fell sharply from 300HKD -> 190HKD within a week or two During bad news , Meituan was fined again and again and price seem to stop falling. That was our accumulation period. Though Q3/21 , earning report reflex slower growth in China but it is still growing. Chinese spending / consumption is still growing in long term and Meituan must be in a part of that. With excellent execution in the past I bet this company keeps adapting and evolving to be in a part of long term China growth.
HKEX:3690Long
by gmhfund
1
China Evergrande Defaults! Now What?China Evergrande, the second-largest real estate developer in China, has been narrowly dodging default for months. The Company has more than US $300 billion in debt that, as it warned the market back in September, it believed would be difficult for it to service. (As an aside, it is believed that China Evergrande could have an additional US $150 billion in debt, off its official financial books). Put simply, the cash flow of the Company, severely dampened by the cooling Chinese housing market, is not enough for it to service interest payments to those from which it borrowed funds, typically in the form of interest-bearing corporate bonds. One such unlucky purchaser of China Evergrande corporate bonds, among others, are off-shore investors. Off-shore bondholders will likely be the least prioritised of the Company’s investors when receiving interest payments or reparations. China Evergrande defaults! Perhaps fortuitously, it was the failure by China Evergrande to make interest payments to this very group of investors that prompted Fitch Ratings to upgrade the Company’s status to “restricted default” on December 9. Interestingly, China Evergrande is the twelfth Chinese real estate firm to default on bonds in 2021, and by far the largest to do so. Now what? Other rating agencies, such as Moody’s and S&P Global, have not been so quick to upgrade their status of China Evergrande. However, S&P Global has noted that China Evergrande’s default is “inevitable”. China Evergrande themselves seem to be ignoring public comment on its failure to meet its obligation, nor has it ceased operations or begun any formal paperwork to address its potential bankruptcy. China Evergrande is currently under restructuring while attempting to continue operations as usual. The restructuring includes renegotiating its liabilities and offloading non-construction arms of the Company at bargain prices such as its property management business, as well as stakes in a major Chinese bank and (strangely enough) a streaming services. Pressure is being applied to the Company’s leaders to speed up its restructuring since the change in its Fitch rating. According to Bloomberg, the China Evergrande restructure is being heavily monitored, if not outright controlled by Chinese Authorities in Beijing and the Company’s home province of Guangdong. Right now, the official line from the Central Bank of China is that the China Evergrande crisis is being handled as per the “principles of marketization and rule of law,”. If more rating agencies follow Fitch Rating in the coming weeks, China Evergrande could slip into something a little more serious than restricted default and the above quote may become a little truer, with Chinese authorities being hamstrung in their ability to interfere with a meltdown.
HKEX:3333
by BlackBull_Markets
Evergrande's SelfdestructionEvergrande shares, symbol 3333, have been getting demolished as of late. On December 6th it broke past its all time lows of 1.88 HKD. This puts Evergrand's stock over 94% down from it's ATH of 32.39 HKD now at 1.77 HKD. The stock is no longer in free fall however, that may not last for long. On December 9th the real estate developer had defaulted on its debt for the first time. Despite the striking resemblance to the fall of Lehman Brothers, Evergrande has made strong efforts to distance itself from being perceived as fundamentally the same thing. Narratives around possible contagion to global markets have fuelled uncertainties and a possible run to risk off. Crypto could suffer due to offshore creditors to Evergrande such as Black Rock who also have exposure to BTC and ETH possibly selling to rebalance or cover losses. Please check out my previous analysis on BTC/USD where I predicted a retrace to $50k with support @ $47k. If you like my content, feedback, likes and coins are encouraged and appreciated! Thank you.
HKEX:3333Short
by Kumo9
855.HKEX_Retracement Trade_LongENTRY: 8.55 SL: 7.67 TP: 10.60 - ADX>20 - RSI>50,RSI<70 - Daily RS +ve - Daily FFI +ve - Daily MACD -ve - Weekly RS +ve - Weekly FFI +ve - Weekly MACD +ve - Moving up since Jul 2021 and retraced to 38.2% fib level. - Good reaction with the rebound above HVN under good volume. - High volume green candles and low volume red candles in current range showing buyers in control. - Market shifting to more defensive stocks in current HK/CN market.
HKEX:855Long
by TRADER-WANNA-BE
What a Cleaning Company Taught me About Risk Management !Read this latest article What I learnt most from this article is not about the share price of this debt laden developer but the poor cleaning company, Fei Yun Cleaning Coy who has US$3 over million unpaid debts owed by Evergrande , the most talked in town property developer, rumoured to go bankrupt. With 90% of his business given to Aoyuan property developer, during the good times, he could afford to expand his business and make money. But the failure to diversify his customers base has painfully and regrettably landed him to sell his beloved car and mortgage his apartments in order to keep his business afloat. Similarly in the good days of the tech craze or now the crypto craze, people are ploughing more money into a single asset, believing the sky is the limit and easy money can be made. While it is true that some has become overnight millionaire or multi millionaire , we must not let these stories influence us too much. Easy come, Easy go, as the saying says. No one single industry can dominate forever just like the Law of Nature. The winter may be harsh and colder on certain times of the years but it will soon passed and Spring will arrive. This is the Law of Nature, nobody can change it. The stock market operates the same, man can manipulate it by propping it up with ultra to negative interest rates, pumping in more money into the system and all other means but the higher it goes, the harder it will fall. The question that God knows is WHEN will that day comes. We are now seeing how a single country like China and its strong regulations can bring down so many listed education players (0ver 90% losses) and even State-owned Investment vehicle like Temasek with its scholars and investment analysts could not prevent it from happening and had to suck thumb and take in the losses. As retail traders, you think you have privy to more sensitive or insider information ? Again, believing in something is sometimes a game of contradiction. It is hard, I know to maintain a lukewarm approach, either you are obsessed with it (be it religion, food, fitness, fame, money,etc) or you are aloof . The in-between are trying to up their level or downgrade to another level. As humans, we strive to improve ourselves, driven by our beliefs that with more effort, more discipline, more focus, we can achieve. And that itself has given us so much on a global scale, look around all the innovations that we enjoyed now that our forefathers lack in their time. We are talking about robo-taxis (Grab - should you be concerned ???), cryptocurrency when not too long ago , we were still carrying cold hard cash (will it be gone when my kids grow up in 10 years time ?) and kids dreaming of becoming youtube influencers (who needs Degrees anymore ? Learn to diversify your RISKS as the first rule of Investing is to not lose your capital. Learn how to protect the downside FIRST and not get overly blinded by the unlimited UPSIDE that is sold to you.
HKEX:3883
by dchua1969
1